An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.
This study has been completed.
Sponsor:
Janssen, LP
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002133
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: April 1996
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.
| Condition | Intervention |
|---|---|
|
Candidiasis, Oral HIV Infections |
Drug: Itraconazole |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects. |
Resource links provided by NLM:
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Patients receive itraconazole oral solution twice daily. Per 08/15/94 amendment, patients with complete resolution of oropharyngeal candidiasis lesions upon completion of treatment are eligible for maintenance treatment on protocol FDA 236C. Patients who decline maintenance are followed for 6 weeks. Patients who relapse during follow-up are re-treated for 14-28 days; if lesions clear, patients may enter the maintenance protocol.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
Patients must have:
- HIV antibody seropositivity or diagnosis of AIDS.
- Confirmed oropharyngeal candidiasis.
- Failed fluconazole treatment within the past 14 days.
- Life expectancy of at least 3 months.
- NO symptoms of esophageal candidiasis (e.g., dysphagia) unless endoscopic exam of esophagus was performed and fungal esophagitis was not present.
- NO prior disseminated candidiasis.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Underlying clinical condition that precludes study completion or places the patient at significant risk.
- Considered unreliable about following physician's directives.
Concurrent Medication:
Excluded:
- Investigational drugs (approved expanded access drugs are permitted).
- Rifampin.
- Rifabutin.
- Phenobarbital.
- Phenytoin.
- Carbamazepine.
- Terfenadine.
- Astemizole.
Patients with the following prior conditions are excluded:
- History of hypersensitivity to imidazole or azole compounds.
- Clinical evidence of significant hepatic disease within the past 2 months.
Prior Medication:
Excluded:
- Investigational drugs within 1 month prior to study entry (approved expanded access drugs are permitted).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002133
Locations
| United States, Alabama | |
| Univ of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35294 | |
| United States, Arkansas | |
| Univ of Arkansas for Med Sciences | |
| Little Rock, Arkansas, United States, 72205 | |
| United States, California | |
| East Bay AIDS Ctr | |
| Berkeley, California, United States, 94705 | |
| Kaiser Permanente Med Ctr | |
| San Francisco, California, United States, 94115 | |
| United States, District of Columbia | |
| George Washington Univ Med Ctr | |
| Washington, District of Columbia, United States, 20037 | |
| Veterans Administration Med Ctr | |
| Washington, District of Columbia, United States, 20422 | |
| Dr Douglas Ward | |
| Washington, District of Columbia, United States, 20009 | |
| United States, Indiana | |
| Infectious Diseases Research Clinic / Indiana Univ Hosp | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Maryland | |
| Natl Inst of Allergy & Infect Dis / Cln Ctr | |
| Bethesda, Maryland, United States, 20892 | |
| United States, Michigan | |
| Ann Arbor Veterans Administration Med Ctr | |
| Ann Arbor, Michigan, United States, 48105 | |
| Wayne State Univ / Harper Hosp | |
| Detroit, Michigan, United States, 48201 | |
| United States, Missouri | |
| Washington Univ | |
| St. Louis, Missouri, United States, 63108 | |
| United States, Ohio | |
| Ohio State Univ Hosp | |
| Columbus, Ohio, United States, 43210 | |
| United States, Oklahoma | |
| Oklahoma City Veterans Administration Med Ctr | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Pennsylvania | |
| Pennsylvania Hosp | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| United States, Tennessee | |
| Infectious Disease Clinic | |
| Nashville, Tennessee, United States, 37212 | |
| United States, Texas | |
| Audie L Murphy Veterans Administration Hosp | |
| San Antonio, Texas, United States, 78284 | |
| United States, Virginia | |
| Univ of Virginia Health Sciences Ctr | |
| Charlottesville, Virginia, United States, 22908 | |
Sponsors and Collaborators
Janssen, LP
More Information
Publications:
Moskovitz B, Wu J, Baruch A, Benken C. Long term safety and efficacy of itraconazole oral solution (IS) for treatment of fluconazole refractory oropharyngeal candidiasis (OC) in HIV-positive patients (pts). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:124 (abstract no 325)
| ClinicalTrials.gov Identifier: | NCT00002133 History of Changes |
| Other Study ID Numbers: | 236B, ITR-USA-94 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
Itraconazole Acquired Immunodeficiency Syndrome AIDS-Related Complex Candidiasis, Oral |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Candidiasis Candidiasis, Oral HIV Seropositivity Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
Mycoses Mouth Diseases Stomatognathic Diseases Fluconazole Itraconazole Hydroxyitraconazole Antifungal Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions 14-alpha Demethylase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on March 10, 2013
